繁體版 / 簡體版
 
R&D PORTFOLIO
/ SNP-630

SNP-630

Indication
Non-alcoholic steatohepatitis (NASH)
Product Advantages
1. Optimized New Chemical Entity
2. First-in-class
3. For NASH and ASH
Status
1. Pre-clinical
2. SNP-630 and/or its active metabolites: some human experience
3. Plan to apply US FDA IND, fast track and breakthrough designation
Competitive Edge
1. Multiple mechanisms of action
2. Direct action on liver
3. Optimal potency
4. Great safety profile
Potential Market
The estimated global market for NASH: 35-40 B per year

Multiple Mechanisms of Action of SNP-6xx


陕西快乐十分中奖技巧 2018年84期四肖中特 (★^O^★)MG日日进财_官方版 p3开机号试机号关注号金码 码报2021免费图 (*^▽^*)MG幸运月游戏说明 吉林快三群 彩票平台网站网址xm88良好 (★^O^★)MG埃及旋转_电子游戏 pt电子游戏app破解版 福建快3推存号码 (^ω^)MG阿拉斯加垂钓新手攻略 赵丽颖启航团队网赚 java水果老虎机 贵州快三开奖结果查询今天 (^ω^)MG财炮连连_电子游戏 为什么要停售高频彩